邁瑞醫療大跌超13% 安圖生物跌停 消息稱安徽開展臨牀檢驗試劑專項帶量採購
格隆匯8月20日丨網傳安徽開展臨牀檢驗試劑專項帶量採購談判議價,涉及5大類產品(下附),約定採購週期為兩年。受此影響,邁瑞醫療大跌超13%,安圖生物跌10%跌停,新產業一度跌超17%,邁克生物跌超5%。注:一份7月14日召開的安徽省臨牀檢驗試劑企業座談會會議記錄在網上流傳,記錄內容稱,本次臨牀檢驗試劑專項帶量採購的模式是帶量談判的議價模式,初步選取5類23個產品進行產品集中帶量議價:第一類是臨牀免疫和血清學專業的腫瘤相關抗原的測定:CEA、AFP、鱗狀細胞癌測定、總前列腺、遊離前列腺、複合前列腺、CA199、CA724、CA153、CA125。第二類是臨牀免疫和血清學專業的感染性疾病,本次只選取了乙肝五項(兩對半)。第三類是臨牀化學專業:僅選擇了心肌疾病相關項目,前期降價的BNP和NT-BNP。第四類是臨牀化學的激素測定:選取了甲狀腺五項,T3、T4、FT3、FT4、TSH。第五類是臨牀微生物學的PCT。參加集中採購的企業範圍是經國家藥監部門批准,在中國大陸銷售的,在安徽醫藥平台銷售的相關檢驗試劑的生產企業。目前約定採購週期為兩年。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.